Logo image of NEOG

NEOGEN CORP (NEOG) Stock Fundamental Analysis

NASDAQ:NEOG - Nasdaq - US6404911066 - Common Stock - Currency: USD

5.42  +0.2 (+3.83%)

After market: 5.499 +0.08 (+1.46%)

Fundamental Rating

4

Taking everything into account, NEOG scores 4 out of 10 in our fundamental rating. NEOG was compared to 187 industry peers in the Health Care Equipment & Supplies industry. NEOG has an average financial health and profitability rating. NEOG is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

NEOG had positive earnings in the past year.
NEOG had a positive operating cash flow in the past year.
In multiple years NEOG reported negative net income over the last 5 years.
Each year in the past 5 years NEOG had a positive operating cash flow.
NEOG Yearly Net Income VS EBIT VS OCF VS FCFNEOG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

With a Return On Assets value of -12.02%, NEOG perfoms like the industry average, outperforming 59.36% of the companies in the same industry.
NEOG has a better Return On Equity (-18.24%) than 62.03% of its industry peers.
Looking at the Return On Invested Capital, with a value of 0.50%, NEOG is in the better half of the industry, outperforming 65.78% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for NEOG is significantly below the industry average of 7.89%.
Industry RankSector Rank
ROA -12.02%
ROE -18.24%
ROIC 0.5%
ROA(3y)1.38%
ROA(5y)3.65%
ROE(3y)1.47%
ROE(5y)3.97%
ROIC(3y)2.71%
ROIC(5y)4.4%
NEOG Yearly ROA, ROE, ROICNEOG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2 4 6 8 10

1.3 Margins

NEOG's Operating Margin of 2.72% is fine compared to the rest of the industry. NEOG outperforms 67.38% of its industry peers.
In the last couple of years the Operating Margin of NEOG has declined.
The Gross Margin of NEOG (48.79%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of NEOG has grown nicely.
Industry RankSector Rank
OM 2.72%
PM (TTM) N/A
GM 48.79%
OM growth 3Y-20.27%
OM growth 5Y-13.36%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.02%
GM growth 5Y1.61%
NEOG Yearly Profit, Operating, Gross MarginsNEOG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40 50

4

2. Health

2.1 Basic Checks

NEOG has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, NEOG has about the same amount of shares outstanding.
Compared to 5 years ago, NEOG has more shares outstanding
The debt/assets ratio for NEOG is higher compared to a year ago.
NEOG Yearly Shares OutstandingNEOG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
NEOG Yearly Total Debt VS Total AssetsNEOG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

NEOG has an Altman-Z score of 0.89. This is a bad value and indicates that NEOG is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.89, NEOG is in line with its industry, outperforming 48.66% of the companies in the same industry.
NEOG has a Debt/Equity ratio of 0.33. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.33, NEOG perfoms like the industry average, outperforming 47.06% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Altman-Z 0.89
ROIC/WACC0.06
WACC7.95%
NEOG Yearly LT Debt VS Equity VS FCFNEOG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

2.3 Liquidity

NEOG has a Current Ratio of 3.91. This indicates that NEOG is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 3.91, NEOG is doing good in the industry, outperforming 65.24% of the companies in the same industry.
A Quick Ratio of 2.45 indicates that NEOG has no problem at all paying its short term obligations.
The Quick ratio of NEOG (2.45) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.91
Quick Ratio 2.45
NEOG Yearly Current Assets VS Current LiabilitesNEOG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

3

3. Growth

3.1 Past

NEOG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.83%.
The Earnings Per Share has been decreasing by -5.21% on average over the past years.
Looking at the last year, NEOG shows a decrease in Revenue. The Revenue has decreased by -2.50% in the last year.
The Revenue has been growing by 17.41% on average over the past years. This is quite good.
EPS 1Y (TTM)-20.83%
EPS 3Y-8.53%
EPS 5Y-5.21%
EPS Q2Q%-16.67%
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y25.42%
Revenue growth 5Y17.41%
Sales Q2Q%-3.42%

3.2 Future

The Earnings Per Share is expected to grow by 6.10% on average over the next years.
The Revenue is expected to grow by 1.81% on average over the next years.
EPS Next Y-15.77%
EPS Next 2Y-8.65%
EPS Next 3Y-1.15%
EPS Next 5Y6.1%
Revenue Next Year-2.43%
Revenue Next 2Y-2.11%
Revenue Next 3Y-0.88%
Revenue Next 5Y1.81%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
NEOG Yearly Revenue VS EstimatesNEOG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
NEOG Yearly EPS VS EstimatesNEOG Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 0.4 0.6

4

4. Valuation

4.1 Price/Earnings Ratio

NEOG is valuated correctly with a Price/Earnings ratio of 14.26.
Based on the Price/Earnings ratio, NEOG is valued cheaply inside the industry as 87.70% of the companies are valued more expensively.
NEOG is valuated rather cheaply when we compare the Price/Earnings ratio to 27.93, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 14.76, NEOG is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NEOG indicates a rather cheap valuation: NEOG is cheaper than 86.63% of the companies listed in the same industry.
NEOG is valuated cheaply when we compare the Price/Forward Earnings ratio to 37.78, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 14.26
Fwd PE 14.76
NEOG Price Earnings VS Forward Price EarningsNEOG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

NEOG's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NEOG is cheaper than 84.49% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 13.3
NEOG Per share dataNEOG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.65%
EPS Next 3Y-1.15%

0

5. Dividend

5.1 Amount

No dividends for NEOG!.
Industry RankSector Rank
Dividend Yield N/A

NEOGEN CORP

NASDAQ:NEOG (7/28/2025, 8:00:02 PM)

After market: 5.499 +0.08 (+1.46%)

5.42

+0.2 (+3.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-09 2025-04-09/bmo
Earnings (Next)07-29 2025-07-29/bmo
Inst Owners128.1%
Inst Owner Change-0.54%
Ins Owners0.33%
Ins Owner Change26.75%
Market Cap1.18B
Analysts82
Price Target7.65 (41.14%)
Short Float %9.82%
Short Ratio3.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.34%
Min EPS beat(2)-10.87%
Max EPS beat(2)11.56%
EPS beat(4)1
Avg EPS beat(4)-8.33%
Min EPS beat(4)-19.26%
Max EPS beat(4)11.56%
EPS beat(8)2
Avg EPS beat(8)50.77%
EPS beat(12)4
Avg EPS beat(12)43.66%
EPS beat(16)4
Avg EPS beat(16)25.09%
Revenue beat(2)0
Avg Revenue beat(2)-1.93%
Min Revenue beat(2)-3.66%
Max Revenue beat(2)-0.19%
Revenue beat(4)1
Avg Revenue beat(4)-0.54%
Min Revenue beat(4)-3.66%
Max Revenue beat(4)2.8%
Revenue beat(8)2
Avg Revenue beat(8)-0.83%
Revenue beat(12)2
Avg Revenue beat(12)-1.27%
Revenue beat(16)4
Avg Revenue beat(16)-0.85%
PT rev (1m)-11.76%
PT rev (3m)-11.76%
EPS NQ rev (1m)-16.67%
EPS NQ rev (3m)-16.67%
EPS NY rev (1m)-1.8%
EPS NY rev (3m)-1.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.05%
Valuation
Industry RankSector Rank
PE 14.26
Fwd PE 14.76
P/S 1.3
P/FCF N/A
P/OCF 17.19
P/B 0.44
P/tB N/A
EV/EBITDA 13.3
EPS(TTM)0.38
EY7.01%
EPS(NY)0.37
Fwd EY6.77%
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)0.32
OCFY5.82%
SpS4.17
BVpS12.26
TBVpS-2.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.02%
ROE -18.24%
ROCE 0.63%
ROIC 0.5%
ROICexc 0.52%
ROICexgc 2.96%
OM 2.72%
PM (TTM) N/A
GM 48.79%
FCFM N/A
ROA(3y)1.38%
ROA(5y)3.65%
ROE(3y)1.47%
ROE(5y)3.97%
ROIC(3y)2.71%
ROIC(5y)4.4%
ROICexc(3y)3.97%
ROICexc(5y)7.43%
ROICexgc(3y)14.92%
ROICexgc(5y)18.11%
ROCE(3y)3.43%
ROCE(5y)5.58%
ROICexcg growth 3Y-23.14%
ROICexcg growth 5Y-16.2%
ROICexc growth 3Y-51.38%
ROICexc growth 5Y-36.83%
OM growth 3Y-20.27%
OM growth 5Y-13.36%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.02%
GM growth 5Y1.61%
F-Score4
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Debt/EBITDA 6.24
Cap/Depr 95.45%
Cap/Sales 12.44%
Interest Coverage 250
Cash Conversion 47.97%
Profit Quality N/A
Current Ratio 3.91
Quick Ratio 2.45
Altman-Z 0.89
F-Score4
WACC7.95%
ROIC/WACC0.06
Cap/Depr(3y)91%
Cap/Depr(5y)106.13%
Cap/Sales(3y)8.23%
Cap/Sales(5y)7.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.83%
EPS 3Y-8.53%
EPS 5Y-5.21%
EPS Q2Q%-16.67%
EPS Next Y-15.77%
EPS Next 2Y-8.65%
EPS Next 3Y-1.15%
EPS Next 5Y6.1%
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y25.42%
Revenue growth 5Y17.41%
Sales Q2Q%-3.42%
Revenue Next Year-2.43%
Revenue Next 2Y-2.11%
Revenue Next 3Y-0.88%
Revenue Next 5Y1.81%
EBIT growth 1Y-66.32%
EBIT growth 3Y-0.01%
EBIT growth 5Y1.73%
EBIT Next Year47.64%
EBIT Next 3Y17.49%
EBIT Next 5Y15.27%
FCF growth 1Y46.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y331.64%
OCF growth 3Y-24.24%
OCF growth 5Y-11.19%